Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
GRANULES
Dr. Krishna Prasad Chigurupati B.Sc. · Hyderabad, India · 4,306 employees
₹841.85
▼-0.42%GRANULES is trading near its 52-week high with strong analyst consensus, reflecting robust revenue growth but at a premium P/E valuation.
Exchange
NSI
Currency
INR
Day range
₹837.75 – ₹868.80
52-week range
₹432.60 – ₹910.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears overvalued relative to its historical P/E and current price near the 52-week high, though growth justifies some premium.
7.5% below the 1-year high · trend down
Hedge-fund memo
Today
Stock is down modestly today but holding above the day's low, showing resilience near highs.
This week
The stock is consolidating near its recent highs after a strong run-up over the past year.
This month
Trading in the upper third of its 1-month range, maintaining bullish momentum.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
24 headlines · 19 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 3 of 4 recent quarters (EPS actual vs. consensus).
7.12 vs 7.7
-7.53% surprise
7.7308 vs 6.7
15.39% surprise
6.19 vs 5.6
10.54% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| GRANULES | 208.61B | 31.21 | — | 17.56% | 22.00% |
| LAURUSLABS | 962.46B | 88.05 | — | 25.39% | 29.10% |
| AUROPHARMA | 915.25B | 26.40 | 9.93% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Increased competition in generic drug markets
Mitigation: Focus on niche therapeutic areas and specialty formulations
Regulatory changes affecting drug pricing
Mitigation: Diversify geographic markets and product portfolio
Business intelligence
Competitive moat
GRANULES benefits from established manufacturing capabilities and a diversified product portfolio in therapeutic segments with moderate barriers to entry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Launch of new specialty pharmaceutical products
Q2 earnings report
Thesis builder
Bull case
Continued strong revenue growth and potential margin expansion through product diversification
Base case
Stable performance in generic markets with gradual margin improvement
Bear case
Increased competition in generic segments and regulatory challenges
Time horizon
12-18 months
Est. CAGR
15-20%
Entry (qual.)
Consider on dips below 800 INR for better risk-reward
Exit (qual.)
Monitor if P/E exceeds 35 or revenue growth falls below 15%
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how GRANULES fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain GRANULES for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
The stock is attractive for long-term investors despite premium valuation, given strong growth prospects.
The Manila Times·1d ago·Eton Pharmaceuticals not Granules India
Issuewire·2d ago·Raj Bioplast different company sector
daily-sun.com·2d ago·tobacco law unrelated to Granules
YourStory.com·2d ago·Decode Age gut microbiome irrelevant
ЭкоПолитика·2d ago·Volyn plastic furniture unrelated
citybuzz -·3d ago·Harvest Table collagen not relevant
Labmate Online·3d ago·starch granules in wheat different topic
Asia Food Beverages·3d ago·igus BPA ban not Granutes India
Juris Hour·3d ago·DEPB TNVAT Madras HC irrelevant
TipRanks·3d ago·earnings transcript published
Sahi·3d ago·FDA no concern Gagillapur facility
Taxscan·3d ago·duplicate of DEPB TNVAT ruling
Business Upturn·3d ago·FDA Gagillapur remediation cleared
Whalesbook·3d ago·Q1 revenue up 22% profit 60%
Whalesbook·3d ago·Q1 FY27 revenue profit strong
Whalesbook·3d ago·Q1 strong growth Marathi
Whalesbook·3d ago·Q1 results Tamil strong gains
Whalesbook·3d ago·Q1 revenue profit surge Gujarati
The Economic Times·3d ago·other stocks listed not Granules
Business Upturn·4d ago·Newgen Software contract irrelevant
NASA Earthdata (.gov)·4d ago·CMR metadata not relevant
Ad-hoc-news.de·4d ago·Symrise PetPal unrelated
scanx.trade·4d ago·debt free sets peptide CDMO targets
MarketsMojo·4d ago·Granules India rated Buy
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
5.38 vs 5.15
4.47% surprise
| 14.94% |
| 5.60% |
| GLENMARK | 638.25B | 46.85 | 14.07% | 16.30% | 14.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹837.75
Resistance (day/52w high)
₹868.80
Volume
9,16,591
Trend
down
RSI (14)
32
MACD
bearish
MA cross
golden
50-day MA
₹808.76
200-day MA
₹653.59
vs 200-DMA
28.8%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.